Published in Curr Opin Clin Nutr Metab Care on May 01, 2009
An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.73
Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle (2012) 1.40
Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev (2013) 1.33
Novel protein ADTRP regulates TFPI expression and function in human endothelial cells in normal conditions and in response to androgen. Blood (2011) 1.12
Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr Rev (2012) 1.11
N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone. J Clin Endocrinol Metab (2009) 0.97
Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr (2010) 0.97
Structural dynamics, intrinsic disorder, and allostery in nuclear receptors as transcription factors. J Biol Chem (2011) 0.96
Current, new and future treatments of osteoporosis. Rheumatol Int (2010) 0.92
Testosterone and vascular function in aging. Front Physiol (2012) 0.89
ERRβ signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells. Br J Cancer (2014) 0.88
Androgen effects on skeletal muscle: implications for the development and management of frailty. Asian J Androl (2014) 0.83
Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem (2010) 0.82
Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes (2014) 0.81
Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. Mol Endocrinol (2015) 0.81
Synthetic Androgens as Designer Supplements. Curr Neuropharmacol (2015) 0.80
Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. Mol Endocrinol (2015) 0.79
Pharmacology of manipulating lean body mass. Clin Exp Pharmacol Physiol (2015) 0.78
Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism. Korean J Urol (2011) 0.77
Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett (2010) 0.76
Advantages and Limitations of Androgen Receptor-Based Methods for Detecting Anabolic Androgenic Steroid Abuse as Performance Enhancing Drugs. PLoS One (2016) 0.75
Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology (2014) 0.75
Myogenic satellite cells: physiology to molecular biology. J Appl Physiol (1985) (2001) 6.27
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2006) 5.58
The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med (1996) 4.10
Androgen receptor (AR) coregulators: an overview. Endocr Rev (2002) 4.01
Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem (1994) 3.87
Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci (2005) 3.14
Leg extensor power and functional performance in very old men and women. Clin Sci (Lond) (1992) 3.03
Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A (2005) 2.89
Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab (2001) 2.79
Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab (2000) 2.68
Body composition in healthy aging. Ann N Y Acad Sci (2000) 2.66
Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab (2004) 2.47
Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev (1999) 2.39
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab (2004) 2.35
Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab (2002) 2.24
Discovery of nonsteroidal androgens. Biochem Biophys Res Commun (1998) 2.21
Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab (2000) 2.17
Epidemiology of sarcopenia. J Am Geriatr Soc (2000) 1.97
Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.91
Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol (1995) 1.80
Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology (2003) 1.74
Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab (1997) 1.73
Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther (2003) 1.73
Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med (2006) 1.72
Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab (1996) 1.70
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol (2003) 1.64
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab (2003) 1.57
Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA (1999) 1.56
Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab (2002) 1.54
Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab (1999) 1.47
Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem (2002) 1.39
Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab (2003) 1.33
Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology (2005) 1.27
Interrelationships of serum testosterone and free testosterone index with FFM and strength in aging men. Am J Physiol Endocrinol Metab (2002) 1.26
Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology (2008) 1.20
Differential anabolic effects of testosterone and amino acid feeding in older men. J Clin Endocrinol Metab (2003) 1.16
Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology (2006) 1.13
Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol (2008) 1.12
Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071). J Med Chem (1999) 1.11
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther (2005) 1.10
Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol (2004) 1.10
New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett (1998) 1.08
Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem (2006) 1.08
Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull (2003) 1.05
The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci (2003) 1.03
An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology (2006) 1.02
Effects of anabolic steroids on the muscle cells of strength-trained athletes. Med Sci Sports Exerc (1999) 1.00
Distribution of different fibre types in human skeletal muscles. A statistical and computational study of the fibre type arrangement in m. vastus lateralis of young, healthy males. J Neurol Sci (1984) 1.00
Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol (2008) 1.00
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res (2006) 0.97
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res (2003) 0.97
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem (2007) 0.96
Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact (2002) 0.94
Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab (2003) 0.86
Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem (2007) 0.84
Synthesis and SAR of tetrahydropyrrolo[1,2-b][1,2,5]thiadiazol-2(3H)-one 1,1-dioxide analogues as highly potent selective androgen receptor modulators. Bioorg Med Chem Lett (2007) 0.79
Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg Med Chem Lett (2007) 0.79
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators. Bioorg Med Chem Lett (2007) 0.77
Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators. J Med Chem (2007) 0.76
Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold. Bioorg Med Chem Lett (2006) 0.76
B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A (2013) 2.47
Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood (2011) 1.64
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
The effects of myostatin on adipogenic differentiation of human bone marrow-derived mesenchymal stem cells are mediated through cross-communication between Smad3 and Wnt/beta-catenin signaling pathways. J Biol Chem (2008) 1.32
Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology (2008) 1.20
Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol (2008) 1.12
Acute exercise activates AMPK and eNOS in the mouse aorta. Am J Physiol Heart Circ Physiol (2011) 1.08
Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell (2013) 1.07
The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids (2008) 1.03
The mechanisms of androgen effects on body composition: mesenchymal pluripotent cell as the target of androgen action. J Gerontol A Biol Sci Med Sci (2003) 1.03
Heterogeneous nucleation and crowding in sickle hemoglobin: an analytic approach. Biophys J (2002) 0.98
Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action. Mol Cell Endocrinol (2011) 0.96
The dynamic structure of the estrogen receptor. J Amino Acids (2011) 0.92
Testosterone improves the regeneration of old and young mouse skeletal muscle. J Gerontol A Biol Sci Med Sci (2012) 0.91
The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle. Endocrinology (2010) 0.89
Acipimox, an inhibitor of lipolysis, attenuates atherogenesis in LDLR-null mice treated with HIV protease inhibitor ritonavir. Arterioscler Thromb Vasc Biol (2009) 0.86
Testosterone plus low-intensity physical training in late life improves functional performance, skeletal muscle mitochondrial biogenesis, and mitochondrial quality control in male mice. PLoS One (2012) 0.86
Fast diffusion of very long chain saturated fatty acids across a bilayer membrane and their rapid extraction by cyclodextrins: implications for adrenoleukodystrophy. J Biol Chem (2009) 0.83
Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab (2007) 0.82
The effects of testosterone deprivation and supplementation on proteasomal and autophagy activity in the skeletal muscle of the male mouse: differential effects on high-androgen responder and low-androgen responder muscle groups. Endocrinology (2013) 0.79
Pressure perturbation calorimetry of lipoproteins reveals an endothermic transition without detectable volume changes. Implications for adsorption of apolipoprotein to a phospholipid surface. Biochemistry (2011) 0.78
The effects of short-term and long-term testosterone supplementation on blood viscosity and erythrocyte deformability in healthy adult mice. Endocrinology (2015) 0.78
Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking β-catenin nuclear translocation and cross-talk with TGF-β signaling in keratinocytes. Wound Repair Regen (2012) 0.76
Loss of muscle strength during sepsis is in part regulated by glucocorticoids and is associated with reduced muscle fiber stiffness. Am J Physiol Regul Integr Comp Physiol (2012) 0.76
Dynamics of coregulator-induced conformational perturbations in androgen receptor ligand binding domain. Mol Cell Endocrinol (2011) 0.76
Research resource: EPSLiM: ensemble predictor for short linear motifs in nuclear hormone receptors. Mol Endocrinol (2014) 0.76
Novel strategies for improving physical function. Horm Res Paediatr (2011) 0.75